Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-08-15.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
Nov 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Takeda Manufacturing Singapore Pte. Ltd. | 15 Aug 2025 | Biologics | On file |
| Biogen MA Inc. | 12 Jul 2024 | Biologics | |
| Biogen U.S. Corporation | 9 Dec 2022 | Biologics | On file |
| Bayer HealthCare LLC | 21 Nov 2019 | Biologics | On file |
Sites inspected
Takeda Manufacturing Singapore Pte. Ltd.Singapore, Singapore1 insp.
Biogen MA Inc.Research Triangle Park, United States1 insp.
Biogen U.S. CorporationDurham, United States1 insp.
Bayer HealthCare LLCBerkeley, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Svetlana A Shestopal1 shared
Thai D Truong1 shared
Travis S Bradley1 shared
Upendra K Katneni1 shared
Brentley S Pittman1 shared
Laurel A Beer1 shared
Alifiya H Ghadiali1 shared
Gregory A Price1 shared
Prajakta A Varadkar1 shared
Zuben E Sauna1 shared
Full investigator report
Get the verbatim findings behind Daniel Lagasse's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site